Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia

• Huafeng Wang,
• Chang Yang,
• Ting Shi,
• Yi Zhang,
• Jiejing Qian,
• Yungui Wang,
• Yongxian Hu,
• Liping Mao,
• Xiujin Ye,
• Fang Liu,
• Zhenfang Xi,
• Lihong Shou,
• Caiyun Fu,
• Hua Naranmandura,
• Jie Jin,
• Hong-Hu Zhu

Affiliations

Huafeng Wang

Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine

Chang Yang

Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine

Ting Shi

Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine

Yi Zhang

Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine

Jiejing Qian

Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine

Yungui Wang

Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine

Yongxian Hu

Institute of Hematology, Zhejiang University

Liping Mao

Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine

Xiujin Ye

Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine

Fang Liu

Department of Hematology, Chengdu Military General Hospital

Zhenfang Xi

Department of Hematology, Linfen People’s Hospital

Lihong Shou

Department of Hematology, The Central Hospital of Huzhou City

Caiyun Fu

College of Life Sciences and Medicine, Zhejiang Sci-Tech University

Hua Naranmandura

Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine

Jie Jin

Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine

Hong-Hu Zhu

Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine